Biotechnology company Flagship Pioneering has unveiled its generative AI platform Expedition Medicines, backed by $50 million in funding. Flagship believes Expedition Medicines will push the boundaries in medicine to enable the creation of first-in-class therapies across oncology, immunology and other diseases. The platform can learn the rules… Read More
Regulatory reform and investment in innovation have supercharged China’s biopharma sector, but will ongoing trade wars with the US pose a risk to growth? By Diana Turner. China’s role in the global biopharma sector has grown significantly in recent years. It is the world’s largest supplier of active… Read More
Over the last few years artificial intelligence (AI) has emerged as a key trend and an important area for investment in drug discovery, whether in preclinical research workflows, clinical trial design or regulation. “AI is evolving faster than any other lab technology with new models and… Read More
Over the last few years artificial intelligence (AI) has emerged as a key trend and an important area for investment in drug discovery, whether in preclinical research workflows, clinical trial design or regulation.
A new AI model developed by Google and Yale researchers has revealed a potential novel cancer therapy pathway. The AI model ‘Cell2Sentence-Scale 27B’ analyses single-cell RNA data using large language models and is designed to be a bridge to make single-cell data accessible, or interpretable, by AI. Read More
Over the last few years artificial intelligence (AI) has emerged as a key trend and an important area for investment in drug discovery, whether in preclinical research workflows, clinical trial design or regulation. This eBook, sponsored by BioIVT, explores the latest AI developments impacting drug discovery, the research areas most… Read More
David Nirschl, Head, Life Sciences Consulting, Thermo Fisher Scientific and Santosh Vijay, Senior Director, Program Management, Thermo Fisher Scientific explore how to harness innovation for speed,… Read More
The recent state visit to the UK by US President Trump was accompanied by the unveiling of a ‘US-UK tech partnership’ on 16 September. DDW speaks to experts at MHA’s life science team, who advise biotechnology and pharma firms in both the UK and… Read More
The use of artificial intelligence (AI) continues to rise, according to the results of the Pistoia Alliance’s annual Lab of the Future survey. The results show that 77% of respondents expect to use AI in the next two years. It also remains the number one investment area… Read More
AI-driven biotechnology company Tres Alchemix has closed its $4.4 million Series A financing round, the company has announced. New funding will be used to accelerate the development of Tres Alchemix’s predictive AI platform and support the opening of a new laboratory at The Oxford Science Park, a… Read More
This paid-for advertorial from CDD Vault appeared in DDW Volume 26 – Issue 4, Fall 2025 CDD Vault outlines what to look for in an SDMP across chemistry and biologics using examples from CDD Vault and other leading platforms. Read More
Artificial intelligence (AI) for drug discovery and development can appear somewhat elusive at times. We have fullyadvanced AI capabilities in several parallel sectors and industries, but experts are cautious to label AI a cure-all, one-shot solution. While technology-driven sectors like cyber security or engineering, for instance, showcase the effects of AI-driven solutions easily, the… Read More
‘How AI is transforming drug discovery’ is an exclusive Guide published by DDW that examines the challenges and opportunities this technology is presenting throughout the industry. Read More
“How AI is transforming drug discovery” is an exclusive guide published by DDW that examines the challenges and opportunities this technology is presenting throughout the industry. It features stories on how AI is shaping drug discovery, how RNA-targeted drug discovery is being pioneered by AI and how the technology… Read More
In this webinar, hosted by DDW and supported by Sapio Sciences, join Dr Rajesh Kumar, Senior Director of Structural Biology at Schrödinger, as he explores how advanced computational methods, AI, and machine learning are revolutionising drug discovery. Dr Kumar highlights how Schrödinger’s physics-based simulations and Free Energy Perturbation (FEP) technology… Read More
A new FREE TO ATTEND webinar ‘Transforming drug discovery with AI and digital labs‘, hosted by DDW and supported by Sapio Sciences, is now open for registrations. On 15 September at 4pm BST, join Dr Rajesh Kumar, Senior Director of Structural Biology at Schrödinger, as he explores how advanced computational… Read More
